Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC.
Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A, Matsushita H, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda M, Nozawa R, Kakimi K, Oka M.
Ohue Y, et al.
J Thorac Oncol. 2019 Dec;14(12):2071-2083. doi: 10.1016/j.jtho.2019.08.008. Epub 2019 Aug 23.
J Thorac Oncol. 2019.
PMID: 31449889
Free article.